{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:25:10Z","timestamp":1790846710040,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,1,15]],"date-time":"2020-01-15T00:00:00Z","timestamp":1579046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,1,15]],"date-time":"2020-01-15T00:00:00Z","timestamp":1579046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["315969"],"award-info":[{"award-number":["315969"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["320107"],"award-info":[{"award-number":["320107"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Antipsychotics are first-line treatment of schizophrenia. They are often accompanied by adjunctive treatments, such as antidepressant (AD) or mood stabilizer (MS), although there is only limited information of their use in first-episode schizophrenia. This study aimed to investigate AD and MS initiation and factors associated with initiation in persons with first-episode schizophrenia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Register-based data was utilized to identify persons who received inpatient care due to schizophrenia during 1996\u20132014 in Finland and who did not use AD or MS at the time of first inpatient care diagnosis of schizophrenia (\n                      <jats:italic>N<\/jats:italic>\n                      \u00a0=\u20097667, mean age 40.2, SD 18.2). Drug purchase data (1995\u20132017) was obtained from the National Prescription register and modelled with PRE2DUP method. Initiations of AD and MS use were followed up 3\u00a0years from first schizophrenia diagnoses. Cox proportional hazard models were used to investigate factors associated with AD or MS initiation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among persons with first-episode schizophrenia, 35.4% initiated AD and 14.1% initiated MS use within three years from diagnoses. Female gender, younger age, and benzodiazepine use were associated with higher risk of AD and MS initiation. The number of previous psychoses was associated with decreased risk of AD and increased risk of MS initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Clinical guidelines rarely recommend the use of AD or MS as adjunctive treatment in persons with schizophrenia. However, this population is often treated with AD or MS. More studies are needed to evaluate benefits and risks of these medications as adjunctive treatment of schizophrenia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00228-020-02830-2","type":"journal-article","created":{"date-parts":[[2020,1,15]],"date-time":"2020-01-15T02:02:41Z","timestamp":1579053761000},"page":"711-718","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Use of antidepressants and mood stabilizers in persons with first-episode schizophrenia"],"prefix":"10.1007","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5897-4583","authenticated-orcid":false,"given":"Arto","family":"Puranen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7316-8360","authenticated-orcid":false,"given":"Marjaana","family":"Koponen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3795-3126","authenticated-orcid":false,"given":"Antti","family":"Tanskanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0400-6798","authenticated-orcid":false,"given":"Jari","family":"Tiihonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3281-934X","authenticated-orcid":false,"given":"Heidi","family":"Taipale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,15]]},"reference":[{"key":"2830_CR1","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, L\u00e4ssig B, Salanti G, Davis JM (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382:951\u2013962. https:\/\/doi.org\/10.1016\/S0140-6736(13)60733-3","journal-title":"Lancet"},{"key":"2830_CR2","unstructured":"(2015) Schizophrenia: Current care guideline. www.kaypahoito.fi. Accessed 5 Jul 2019"},{"key":"2830_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/schbul\/sbp116","volume":"36","author":"RW Buchanan","year":"2010","unstructured":"Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, Keller W, Schizophrenia Patient Outcomes Research Team (PORT) (2010) The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 36:71\u201393. https:\/\/doi.org\/10.1093\/schbul\/sbp116","journal-title":"Schizophr Bull"},{"key":"2830_CR4","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1176\/appi.ajp.2016.15081035","volume":"173","author":"B Helfer","year":"2016","unstructured":"Helfer B, Samara MT, Huhn M et al (2016) Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis. Am J Psychiatry 173:876\u2013886. https:\/\/doi.org\/10.1176\/appi.ajp.2016.15081035","journal-title":"Am J Psychiatry"},{"key":"2830_CR5","doi-asserted-by":"publisher","unstructured":"Wang Y, Xia J, Helfer B, Li C, Leucht S (2016) Valproate for schizophrenia (review). Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD004028.pub4","DOI":"10.1002\/14651858.CD004028.pub4"},{"key":"2830_CR6","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/acps.12854","volume":"137","author":"B Galling","year":"2018","unstructured":"Galling B, Vernon JA, Pagsberg AK, Wadhwa A, Grudnikoff E, Seidman AJ, Tsoy-Podosenin M, Poyurovsky M, Kane JM, Correll CU (2018) Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia. Acta Psychiatr Scand 137:187\u2013205. https:\/\/doi.org\/10.1111\/acps.12854","journal-title":"Acta Psychiatr Scand"},{"key":"2830_CR7","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/YCO.0b013e3283366427","volume":"23","author":"M Zink","year":"2010","unstructured":"Zink M, Englisch S, Meyer-Lindenberg A (2010) Polypharmacy in schizophrenia. Curr Opin Psychiatry 23:103\u2013111. https:\/\/doi.org\/10.1097\/YCO.0b013e3283366427","journal-title":"Curr Opin Psychiatry"},{"key":"2830_CR8","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.schres.2019.01.028","volume":"208","author":"DC Goff","year":"2019","unstructured":"Goff DC, Freudenreich O, Cather C, Holt D, Bello I, Diminich E, Tang Y, Ardekani BA, Worthington M, Zeng B, Wu R, Fan X, Li C, Troxel A, Wang J, Zhao J (2019) Citalopram in first episode schizophrenia: the DECIFER trial. Schizophr Res 208:331\u2013337. https:\/\/doi.org\/10.1016\/j.schres.2019.01.028","journal-title":"Schizophr Res"},{"key":"2830_CR9","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1001\/jamapsychiatry.2018.4489","volume":"76","author":"TS Stroup","year":"2019","unstructured":"Stroup TS, Gerhard T, Crystal S, Huang C, Tan Z, Wall MM, Mathai C, Olfson M (2019) Comparative effectiveness of adjunctive psychotropic medications in patients with schizophrenia. JAMA Psychiatry 76:508\u2013515. https:\/\/doi.org\/10.1001\/jamapsychiatry.2018.4489","journal-title":"JAMA Psychiatry"},{"key":"2830_CR10","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1176\/appi.ajp.2015.15050618","volume":"173","author":"J Tiihonen","year":"2016","unstructured":"Tiihonen J, Mittendorfer-Rutz E, Torniainen M et al (2016) Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: an observational follow-up study. Am J Psychiatry 173:600\u2013606. https:\/\/doi.org\/10.1176\/appi.ajp.2015.15050618","journal-title":"Am J Psychiatry"},{"key":"2830_CR11","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1176\/ps.2006.57.8.1094","volume":"57","author":"MH Chakos","year":"2006","unstructured":"Chakos MH, Glick ID, Miller AL, Hamner MB, Miller DD, Patel JK, Tapp A, Keefe RS, Rosenheck RA (2006) Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatr Serv 57:1094\u20131101. https:\/\/doi.org\/10.1176\/ps.2006.57.8.1094","journal-title":"Psychiatr Serv"},{"key":"2830_CR12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.schres.2012.01.008","volume":"136","author":"S Himelhoch","year":"2012","unstructured":"Himelhoch S, Slade E, Kreyenbuhl J et al (2012) Antidepressant prescribing patterns among VA patients with schizophrenia. Schizophr Res 136:32\u201335. https:\/\/doi.org\/10.1016\/j.schres.2012.01.008","journal-title":"Schizophr Res"},{"key":"2830_CR13","doi-asserted-by":"publisher","unstructured":"Olfson M, Marcus SC, Wan GJ (2009) Treatment patterns for schizoaffective disorder and schizophrenia among Medicaid patients. Psychiatr Serv 60:210\u2013216. https:\/\/doi.org\/10.1176\/ps.2009.60.2.210","DOI":"10.1176\/ps.2009.60.2.210"},{"key":"2830_CR14","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1111\/j.1742-1241.2009.02191.x","volume":"63","author":"J Karagianis","year":"2009","unstructured":"Karagianis J, Novick D, Pecenak J, Haro JM, Dossenbach M, Treuer T, Montgomery W, Walton R, Lowry AJ (2009) Worldwide-schizophrenia outpatient health outcomes (W-SOHO): baseline characteristics of pan-regional observational data from more than 17,000 patients. Int J Clin Pract 63:1578\u20131588. https:\/\/doi.org\/10.1111\/j.1742-1241.2009.02191.x","journal-title":"Int J Clin Pract"},{"key":"2830_CR15","unstructured":"WHO (2018) ATC-DDD: structure and principles. Methodology, WHO Collaborating Centre for Drug Statistic. https:\/\/www.whocc.no\/atc\/structure_and_principles\/. Accessed 29 May 2019"},{"key":"2830_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12911-015-0140-z","volume":"15","author":"A Tanskanen","year":"2015","unstructured":"Tanskanen A, Taipale H, Koponen M, Tolppanen AM, Hartikainen S, Ahonen R, Tiihonen J (2015) From prescription drug purchases to drug use periods - a second generation method (PRE2DUP). BMC Med Inform Decis Mak 15:1\u201313. https:\/\/doi.org\/10.1186\/s12911-015-0140-z","journal-title":"BMC Med Inform Decis Mak"},{"key":"2830_CR17","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/pds.4426","volume":"27","author":"J Forsman","year":"2018","unstructured":"Forsman J, Taipale H, Masterman T et al (2018) Comparison of dispensed medications and forensic-toxicological findings to assess pharmacotherapy in the Swedish population 2006 to 2013. Pharmacoepidemiol Drug Saf 27:1112\u20131122. https:\/\/doi.org\/10.1002\/pds.4426","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2830_CR18","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2147\/CLEP.S116160","volume":"8","author":"H Taipale","year":"2016","unstructured":"Taipale H, Tanskanen A, Koponen M, Tolppanen AM, Tiihonen J, Hartikainen S (2016) Agreement between PRE2DUP register data modeling method and comprehensive drug use interview among older persons. Clin Epidemiol 8:363\u2013371. https:\/\/doi.org\/10.2147\/CLEP.S116160","journal-title":"Clin Epidemiol"},{"key":"2830_CR19","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1017\/S1461145711000563","volume":"14","author":"K Sim","year":"2011","unstructured":"Sim K, Yong KH, Chan YH, Tor PC, Xiang YT, Wang CY, Lee EH, Fujii S, Yang SY, Chong MY, Ungvari GS, Si T, He YL, Chung EK, Chee KY, Trivedi J, Udomratn P, Shinfuku N, Kua EH, Tan CH, Sartorius N, Baldessarini RJ (2011) Adjunctive mood stabilizer treatment for hospitalized schizophrenia patients: Asia psychotropic prescription study (2001-2008). Int J Neuropsychopharmacol 14:1157\u20131164. https:\/\/doi.org\/10.1017\/S1461145711000563","journal-title":"Int J Neuropsychopharmacol"},{"key":"2830_CR20","doi-asserted-by":"publisher","unstructured":"Huband N, Ferriter M, Nathan R, Jones H (2010) Antiepileptics for aggression and associated impulsivity (review). Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD003499.pub3","DOI":"10.1002\/14651858.CD003499.pub3"},{"key":"2830_CR21","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1080\/00048670701732699","volume":"42","author":"VA Morgan","year":"2008","unstructured":"Morgan VA, Castle DJ, Jablensky AV (2008) Do women express and experience psychosis differently from men? Epidemiological evidence from the Australian National Study of low prevalence (psychotic) disorders. Aust N Z J Psychiatry 42:74\u201382. https:\/\/doi.org\/10.1080\/00048670701732699","journal-title":"Aust N Z J Psychiatry"},{"key":"2830_CR22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.schres.2009.07.002","volume":"114","author":"SM Cotton","year":"2009","unstructured":"Cotton SM, Lambert M, Schimmelmann BG et al (2009) Gender differences in premorbid, entry, treatment, and outcome characteristics in a treated epidemiological sample of 661 patients with first episode psychosis. Schizophr Res 114:17\u201324. https:\/\/doi.org\/10.1016\/j.schres.2009.07.002","journal-title":"Schizophr Res"},{"key":"2830_CR23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.eurpsy.2011.11.003","volume":"28","author":"B Dell\u2019osso","year":"2013","unstructured":"Dell\u2019osso B, Lader M (2013) Do benzodiazepines still deserve a major role in the treatment of psychiatric disorders? A critical reappraisal. Eur Psychiatry 28:7\u201320. https:\/\/doi.org\/10.1016\/j.eurpsy.2011.11.003","journal-title":"Eur Psychiatry"},{"key":"2830_CR24","first-page":"92","volume":"29","author":"CU Correll","year":"2017","unstructured":"Correll CU, Yu X, Xiang Y, Kane JM, Masand P (2017) Biological treatment of acute agitation or aggression with schizophrenia or bipolar disorder in the inpatient setting. Ann Clin Psychiatry 29:92\u2013107","journal-title":"Ann Clin Psychiatry"},{"key":"2830_CR25","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1001\/jamapsychiatry.2017.1322","volume":"74","author":"J Tiihonen","year":"2017","unstructured":"Tiihonen J, Mittendorfer-Rutz E, Majak M, Meht\u00e4l\u00e4 J, Hoti F, Jedenius E, Enkusson D, Leval A, Sermon J, Tanskanen A, Taipale H (2017) Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiatry 74:686\u2013693. https:\/\/doi.org\/10.1001\/jamapsychiatry.2017.1322","journal-title":"JAMA Psychiatry"},{"key":"2830_CR26","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/BF00789044","volume":"32","author":"M Isohanni","year":"1997","unstructured":"Isohanni M, M\u00e4kikyr\u00f6 T, Moring J, R\u00e4s\u00e4nen P, Hakko H, Partanen U, Koiranen M, Jones P (1997) A comparison of clinical and research DSM-III-R diagnoses of schizophrenia in a Finnish national birth cohort. Soc Psychiatry Psychiatr Epidemiol 32:303\u2013308. https:\/\/doi.org\/10.1007\/BF00789044","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"2830_CR27","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1176\/appi.ajp.2018.17091001","volume":"175","author":"J Tiihonen","year":"2018","unstructured":"Tiihonen J, Tanskanen A, Taipale H (2018) 20-year Nationwide follow-up study on discontinuation of antipsychotic treatment in first-episode schizophrenia. Am J Psychiatry 175:765\u2013773. https:\/\/doi.org\/10.1176\/appi.ajp.2018.17091001","journal-title":"Am J Psychiatry"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-020-02830-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-020-02830-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-020-02830-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T02:45:44Z","timestamp":1610592344000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-020-02830-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,15]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["2830"],"URL":"https:\/\/doi.org\/10.1007\/s00228-020-02830-2","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,15]]},"assertion":[{"value":"8 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Jari Tiihonen, Heidi Taipale and Antti Tanskanen have participated in research projects funded by grants from Janssen-Cilag and Eli Lilly to their employing institution. Jari Tiihonen reports personal fees from the Finnish Medicines Agency (Fimea), European Medicines Agency (EMA), Eli Lilly, Janssen-Cilag, Lundbeck, and Otsuka; is a member of advisory board for Lundbeck, and has received grants from the Stanley Foundation and Sigrid Jus\u00e9lius Foundation. The other authors report no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}